Trial Profile
CA209-382 A Randomized Phase 2 Open Label Study of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in Recurrent Glioblastoma (GBM)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Bevacizumab
- Indications Glioblastoma
- Focus Therapeutic Use
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 10 Jan 2020 Planned End Date changed from 1 Jun 2021 to 30 Dec 2022.
- 10 Jan 2020 Planned primary completion date changed from 1 Dec 2020 to 30 Dec 2020.